Publications by authors named "J Doorduin"

Purpose: Preclinical studies suggest that trimebutine could be a potential treatment for glioblastoma. The aim of this study was to investigate the distribution, kinetics and tumor accumulation of [C]trimebutine.

Method: A proliferation assay and cell scratch healing assay were performed to confirm the antitumor effects of trimebutine on C6 glioma cells in-vitro.

View Article and Find Full Text PDF

Background And Objectives: Nemaline myopathy type 6 (NEM6) is the most prevalent type of nemaline myopathy in the Netherlands. Because a detailed clinical characterization is not available yet, we here provide a detailed assessment of 24 patients.

Methods: In this cross-sectional study, we performed a full clinical assessment (medical history and neurologic examination) in patients with NEM6.

View Article and Find Full Text PDF
Article Synopsis
  • Mechanical ventilation can negatively impact diaphragm and lung function, highlighting the need for protective strategies that support natural respiratory efforts while minimizing lung damage.
  • Recent advancements in monitoring techniques and interventions, such as noninvasive ventilator maneuvers and various measurement tools, help assess and manage respiratory effort and lung stress effectively.
  • Achieving optimal lung- and diaphragm-protective ventilation requires a holistic understanding of breathing physiology, combined with careful application of multiple interventions and continuous monitoring.
View Article and Find Full Text PDF

Most pharmacological treatments for depression target monoamine transporters and about 50 % of treated patients attain symptomatic remission. Once remission is attained, it is hard to distinguish the changes on brain monoaminergic transmission induced by the antidepressants, from those associated to remission per se. In this study, we aimed at studying the brain of spontaneously remitted rats from repeated social defeat (RSD)-induced depression in terms of dopamine D/D receptor and serotonin transporter (SERT) availability, showing absence of depressive symptoms 2 weeks after RSD.

View Article and Find Full Text PDF